Eli Lilly gets drug regulator nod for Alzheimer's disease medication

Core Insights - Eli Lilly and Company (India) has received approval from the Central Drugs Standard Control Organization (CDSCO) for donanemab, a drug aimed at treating Alzheimer's disease in adults with early symptomatic stages [1][2] - The approval is seen as a significant milestone in addressing the urgent needs of individuals living with Alzheimer's disease in India [2] - Donanemab is designed to target amyloid plaques and slow cognitive decline, potentially improving the quality of life for patients and their families [3] Industry Context - Alzheimer's disease is the most common cause of dementia globally, accounting for 60-70% of dementia cases [3] - The disease remains highly underdiagnosed in India, with projections indicating that over 8 million people will be living with dementia in the country by 2030, with Alzheimer's representing the largest share of these cases [4]